Highbridge Capital Management’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-10,800
Closed -$414K 1905
2017
Q3
$414K Buy
+10,800
New +$453K 0.01% 1039
2016
Q2
Sell
-16,600
Closed -$445K 1691
2016
Q1
$445K Buy
+16,600
New +$406K 0.01% 1025
2015
Q1
Sell
-69,700
Closed -$1.38M 1552
2014
Q4
$1.38M Sell
69,700
-87,600
-56% -$1.96M 0.02% 561
2014
Q3
$3.13M Buy
+157,300
New +$3.31M 0.04% 378
2014
Q2
Sell
-15,100
Closed -$194K 1251
2014
Q1
$194K Buy
+15,100
New +$217K ﹤0.01% 973

Other funds holding RGEN

Highbridge Capital Management's RGEN Position: Q4 2017 in Review

Highbridge Capital Management sold out of Repligen (RGEN) in Q4 2017, closing a stake of 13,845 shares — an estimated $531K sold.

Highbridge Capital Management first reported a position in RGEN in Q3 2016 and held it in 2 quarters. The position peaked at $531K in Q3 2017. 184 funds tracked by Wall St. Rank hold RGEN as of Q4 2017.

  • Highbridge Capital Management reported no remaining Repligen position as of Q4 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 13,845 Repligen shares in Q4 2017, an estimated $531K.
  • Highbridge Capital Management first reported a position in Repligen in Q3 2016 and held it in 2 quarters.
  • Highbridge Capital Management's Repligen position peaked at $531K in Q3 2017.
  • 184 funds tracked by Wall St. Rank held Repligen as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.